Sundrug, JP3336600006

Sundrug stock: first-half operating profit rises 4.2%

Published on 11/18/2026 at 02:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sundrug stock follows stronger first-half sales and operating profit through September. The company kept its full-year forecast unchanged.

Half-year results point to steady growth

  • Revenue increased during the six months through September 2026.
  • Drugstore and discount-store operations both contributed to growth.
  • Sundrug maintained its full-year outlook for the fiscal year ending March 2027.
Sundrug, JP3336600006, Illustration mit AI erstellt.

Sundrug reported higher revenue and operating profit for the six months ended September 30, 2026. The figures, published on November 13 and covered by Kabutan, show continued growth in the company's fiscal first half.

Revenue rose 3.6 percent year over year to JPY 433.475 billion. Operating profit increased 4.2 percent to JPY 24.030 billion, while net income advanced 1.4 percent to JPY 15.479 billion. Ordinary profit grew 2.4 percent to JPY 23.446 billion.

Drugstores and discount stores both expand

The drugstore business generated revenue of JPY 273.741 billion, an increase of 2.5 percent. Operating profit in the segment rose 4.0 percent, supported by store renovations as well as pharmacy and e-commerce activity.

Revenue at the discount-store business increased 4.9 percent to JPY 190.662 billion, while operating profit climbed 4.6 percent to JPY 10.221 billion. Sundrug ended September with 1,600 stores across the two formats.

Full-year outlook remains unchanged

Sundrug kept its forecast for the fiscal year ending March 2027 unchanged. The company expects revenue of JPY 876.0 billion, operating profit of JPY 48.8 billion and net income of JPY 32.15 billion.

The first-half operating-profit result represented 49.2 percent of the full-year plan. Ordinary profit reached 48.7 percent of its annual target, close to the five-year average cited in the results report.

Japan retail network faces competition

Sundrug operates a retail store network in Japan and focuses on convenient locations, health-related expertise and low-cost operations. Its business is shaped by an aging population, lower birth rates and competition among industry participants for new stores. The company also points to mergers among major firms as a force driving consolidation in Japan's retail sector.

Sundrug company facts

  • Company: Sundrug Co., Ltd.
  • ISIN: JP3336600006
  • Tokyo ticker: 9989
  • Reporting period: Six months ended September 30, 2026
  • Revenue: JPY 433.475 billion
  • Operating profit: JPY 24.030 billion
  • Net income: JPY 15.479 billion

Japan's broader market backdrop is covered in the Nikkei 225 market overview.

More news and analyses on Sundrug stock.

Disclaimer...
en | JP3336600006 | SUNDRUG | boerse | 70529073 | bgmi